Mycoplasma gallisepticum in Poultry: Diagnosis and Management Strategies

Introduction

Mycoplasma gallisepticum is a bacterial pathogen of major economic importance in commercial poultry production worldwide. As a member of the class Mollicutes, M. gallisepticum lacks a cell wall and possesses a reduced genome, which constrains its metabolic capacity and renders it highly dependent on host-derived nutrients [1, 2]. The organism is the primary etiological agent of chronic respiratory disease (CRD) in chickens and infectious sinusitis in turkeys, and it is also associated with significant reductions in egg production and hatchability in breeding and laying flocks [3, 4]. The disease complex is often exacerbated by concurrent viral or bacterial infections, environmental stressors, and suboptimal management conditions [5, 6]. This article provides a detailed, evidence-based review of the clinical presentation, diagnostic approaches, and integrated management strategies for M. gallisepticum in poultry.

Pathogenesis and Clinical Signs

M. gallisepticum colonizes the respiratory epithelium of the upper and lower respiratory tract through adhesion mediated by surface lipoproteins and cytadhesins, most notably the GapA protein [7, 8]. The bacterium induces a chronic inflammatory response characterized by lymphoplasmacytic infiltration, mucosal hyperplasia, and exudate accumulation within the trachea, air sacs, and lungs [9]. Clinical signs typically emerge after an incubation period of 1 to 3 weeks and vary with host age, immune status, and concurrent infections.

Chronic Respiratory Disease

CRD is the classic manifestation in chickens. Affected birds exhibit rales, coughing, sneezing, ocular discharge, and nasal exudate [10]. In uncomplicated cases, mortality is low; however, secondary infections with agents such as Avian Pathogenic Escherichia coli (APEC) or infectious bronchitis virus can precipitate severe airsacculitis, pericarditis, and increased mortality [11, 12]. The pathogenesis of CRD involves a biphasic immune response, with early innate defenses failing to clear the infection, followed by a delayed and often ineffective humoral response [13].

Egg Production Drop

In layers and breeders, M. gallisepticum infection causes a marked decline in egg production, often by 10 to 30 percent, and reduces egg quality (thin shells, abnormal shape) [14, 15]. The mechanism includes salpingitis and oophoritis, with the organism detected in the oviduct and ovarian follicles [16]. Vertical transmission to progeny occurs via infected eggs, perpetuating the infection cycle in subsequent generations [17].

Sinusitis in Turkeys

Turkeys develop severe infraorbital sinus swelling along with respiratory distress, which can lead to substantial morbidity and mortality [18].

Diagnostic Approaches

Accurate diagnosis is critical for implementing control measures and monitoring flock health. Diagnostic methods fall into three categories: culture and isolation, serological tests, and molecular assays.

Culture and Isolation

Traditional culture on enriched media (e.g., Frey medium) remains a gold standard for definitive identification but is slow (7 to 21 days) and requires specialized expertise [19]. Colonies exhibit a characteristic fried-egg morphology. Immunofluorescence or immunoperoxidase staining of colonies can confirm species identity [20].

Serological Diagnostics

Serological tests detect antibodies against M. gallisepticum and are widely used for flock-level screening. The three principal methods are the rapid serum agglutination (RSA) test, the hemagglutination inhibition (HI) test, and enzyme-linked immunosorbent assays (ELISAs) [21, 22]. The Enzyme-Linked Immunosorbent Assay (ELISA) for Feline Leukemia Virus p27 Antigen Detection and Diagnostic Interpretation article discusses antigen detection but the underlying principles are analogous for antibody detection in poultry.

RSA is a simple, inexpensive test that uses stained antigen. It is sensitive but prone to false positives, particularly in vaccinated flocks or those with cross-reacting antibodies to other Mycoplasma species (e.g., M. synoviae) [23]. HI is more specific and quantifies antibody titers, but it is labor-intensive and requires fresh red blood cells [24]. Commercial ELISA kits offer high throughput and objective endpoint measurement (optical density), with reported sensitivities and specificities above 90 percent [25]. However, serology cannot distinguish between vaccinated and naturally infected birds unless specific vaccine markers are used.

Molecular Diagnostics

Polymerase chain reaction (PCR) assays have become the frontline tool for rapid, specific detection of M. gallisepticum. Real-time PCR (qPCR) targeting the 16S rRNA gene or the mgc2 gene provides results within hours and can detect as few as 10 to 100 genome copies [26, 27]. PCR offers several advantages over serology: it detects the pathogen directly, discriminates among Mycoplasma species, and can be applied to a variety of sample types including tracheal swabs, choanal cleft swabs, and tissue specimens [28, 29]. Multiplex PCR panels that simultaneously detect M. gallisepticum, M. synoviae, and other respiratory pathogens (e.g., infectious bronchitis virus, avian influenza virus) are increasingly used in diagnostic workflows [30]. The article on Avian Influenza A(H5N1) in Poultry and Wild Birds: Current Epidemiology, Molecular Diagnostics, and Biosecurity describes analogous molecular approaches.

Comparison of Diagnostic Methods

Table 1 summarizes the key characteristics of culture, serology, and PCR.

Table 1. Diagnostic Methods for Mycoplasma gallisepticum

Management Strategies

Management of M. gallisepticum infection involves a combination of antimicrobial therapy, vaccination, biosecurity, and eradication programs.

Antimicrobial Therapy

Because M. gallisepticum lacks a cell wall, beta-lactam antibiotics are ineffective. Drugs that inhibit protein synthesis, such as tylosin, tilmicosin, and oxytetracycline, have historically been used [31, 32]. However, antimicrobial resistance is a growing concern, with reports of resistance to macrolides and tetracyclines in field isolates [33, 34]. Susceptibility testing via broth microdilution should guide drug selection. Therapy can suppress clinical signs and reduce shedding, but it rarely eliminates the infection from a flock [35].

Vaccination

Vaccination is an important component of control, especially in multi-age layer flocks and breeder operations. Three types of vaccines are available:

• Live attenuated vaccines: The F strain, ts-11, and 6/85 strains are commercially used. The F strain is moderately virulent but provides good protection in layers; it can spread horizontally. The ts-11 and 6/85 strains are temperature-sensitive mutants that are safer for use in susceptible flocks [36, 37].
• Inactivated (bacterin) vaccines: These induce a strong humoral response and reduce egg production drop but offer less protection against respiratory colonization [38].
• Recombinant vaccines: Vectored vaccines using fowlpox virus or avian adenovirus expressing M. gallisepticum immunogens (e.g., GapA, MGC1) are under development and show promise in experimental trials [39, 40].

Vaccination programs must consider the immune status of the flock, the local epidemiological situation, and the risk of reversion to virulence (for live vaccines) [41].

Biosecurity and Eradication

Biosecurity measures aim to prevent introduction and spread of M. gallisepticum. Key practices include:

• Maintaining closed flocks or sourcing from M. gallisepticum-free suppliers.
• Implementing all-in/all-out production systems with thorough cleaning and disinfection between cycles.
• Using dedicated footwear, clothing, and equipment for each house.
• Controlling wild birds, rodents, and insects that may act as mechanical vectors [42, 43].

Eradication is feasible in breeding stocks through serological surveillance and culling of positive birds. The National Poultry Improvement Plan (NPIP) in the United States has successfully eliminated M. gallisepticum from primary breeding flocks through rigorous testing and depopulation [44]. In commercial layers, eradication is more challenging due to the higher population density and longer production cycles, but vaccination combined with strategic medication can reduce prevalence [45].

Diagnostic and Management Decision Tree

The following Mermaid diagram illustrates a recommended workflow for diagnosis and management.

flowchart TD
    A[Flocks with respiratory signs or egg drop], > B{Initial screening}
    B, > C[Collect tracheal swabs and serum]
    C, > D[Perform qPCR and ELISA]
    D, > E{PCR positive?}
    E, >|Yes| F[Confirm with culture or HI if needed]
    E, >|No| G[Consider serology: ELISA positive?]
    G, >|Yes| H[Possible past exposure or vaccination. Monitor and retest]
    G, >|No| I[Unlikely M. gallisepticum; look for other pathogens]
    F, > J{First detection in a naive flock?}
    J, >|Yes| K[Initiate biosecurity, quarantine, consider depopulation]
    J, >|No| L[Assess vaccination status]
    L, > M[Vaccinated?]
    M, >|Yes| N[If clinical signs persist, check for vaccine failure or resistance]
    M, >|No| O[Implement vaccination program plus antimicrobial therapy based on sensitivity]
    N, > P[Review antimicrobial use, booster vaccination]
    O, > Q[Monitor clinical response and retest in 4 weeks]
    Q, > R{Clinical improvement and PCR negative?}
    R, >|Yes| S[Continue biosecurity; periodic surveillance]
    R, >|No| T[Consider depopulation and disinfection]

Conclusion

Mycoplasma gallisepticum remains a persistent challenge in poultry production due to its ability to cause chronic respiratory disease and egg production losses, its efficient vertical transmission, and the limitations of single-modality control measures. Successful management requires a multifaceted approach that integrates rapid molecular diagnostics (especially qPCR) with serological surveillance, prudent antimicrobial use guided by susceptibility testing, vaccination tailored to the production system, and rigorous biosecurity. Continued research into novel vaccine platforms and antimicrobial alternatives, such as bacteriophages and antimicrobial peptides, may provide additional tools in the fight against this economically significant pathogen.

References

[1] Razin S, Yogev D, Naot Y. Molecular biology and pathogenicity of mycoplasmas. Microbiol Mol Biol Rev. 62(4):1094-1156.

[2] Kleven SH. Mycoplasmas in poultry. In: Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. World Organisation for Animal Health.

[3] Ley DH, Yoder HW. Mycoplasma gallisepticum infection. In: Diseases of Poultry. 13th ed. Wiley-Blackwell.

[4] Bradbury JM. Avian mycoplasmas. In: Poultry Diseases. 6th ed. Saunders Elsevier.

[5] Evans JD, Leigh SA, Branton SL, et al. Molecular characterization of Mycoplasma gallisepticum isolates from commercial broiler and layer flocks. Avian Dis. 53(3):407-414.

[6] Nascimento ER, Pereira VL, Nascimento MG, et al. Antimicrobial susceptibility of Mycoplasma gallisepticum and Mycoplasma synoviae isolated from commercial poultry in Brazil. Braz J Microbiol. 46(2):577-582.

[7] Raviv Z, Callison SA, Ferguson-Noel NM, et al. The Mycoplasma gallisepticum GapA cytadhesin is a virulence factor. Infect Immun. 75(12):5634-5643.

[8] May M, Brown DR, Dybvig K. Mycoplasma gallisepticum: molecular pathogenesis and vaccine development. Vet Microbiol. 160(3-4):301-311.

[9] Simecka JW, Davis JK, Davidson MK, et al. Mycoplasma diseases of animals. In: Mycoplasma Diseases. Academic Press.

[10] Jordan FT. Respiratory diseases of poultry. Vet Rec. 109(4):81-87.

[11] Peebles ED, Branton SL, Gerard PD, et al. Effects of Mycoplasma gallisepticum infection and environmental temperature on the performance of broilers. Poult Sci. 81(7):1025-1031.

[12] Nakamura K, Ueda H, Tanimura N, et al. Pathological studies of airsacculitis in broiler chickens. Avian Pathol. 31(5):487-496.

[13] Gaunson JE, Philip CJ, Whithear KG, et al. The cellular immune response in chickens infected with Mycoplasma gallisepticum. Avian Pathol. 35(4):291-301.

[14] Branton SL, Lott BD, May JD, et al. The effect of Mycoplasma gallisepticum infection on the performance of laying hens. Poult Sci. 66(1):44-50.

[15] Peebles ED, Branton SL, Whitmarsh KE, et al. Effects of egg production and egg quality after experimental infection of laying hens with Mycoplasma gallisepticum. Poult Sci. 72(6):1097-1102.

[16] Lierz M, Hafez HM. Detection of Mycoplasma gallisepticum and Mycoplasma synoviae in the reproductive tract of chickens. Avian Dis. 53(1):125-128.

[17] Bencina D, Bradbury JM, Kleven SH. Transmission of Mycoplasma gallisepticum through the egg. Vet Rec. 124(2):39-40.

[18] Glisson JR, Liebman B. Mycoplasma gallisepticum infection in turkeys. Avian Dis. 43(2):236-240.

[19] Frey ML, Hanson RP, Anderson DP. A medium for the isolation of avian mycoplasmas. Am J Vet Res. 29(11):2163-2171.

[20] Kleven SH, Fletcher OJ, Davis RB. Immunofluorescence staining for identification of Mycoplasma gallisepticum. Avian Dis. 15(3):487-494.

[21] Talkington FD, Kleven SH, Brown J. An enzyme-linked immunosorbent assay for detecting antibodies to Mycoplasma gallisepticum. Avian Dis. 29(1):53-62.

[22] Avakian AP, Kleven SH. Evaluation of commercial ELISA kits for the detection of antibodies to Mycoplasma gallisepticum. Avian Dis. 32(3):497-502.

[23] Yoder HW. A comparison of the serum plate agglutination and hemagglutination-inhibition tests for the detection of antibodies to Mycoplasma gallisepticum. Avian Dis. 8(4):495-501.

[24] Whithear KG, Ghiocas E, Hughes LA. Hemagglutination inhibition test for Mycoplasma gallisepticum. Aust Vet J. 58(3):97-100.

[25] Kempf I, Gesbert F, Guittet M, et al. Evaluation of two commercial ELISA kits for the detection of antibodies to Mycoplasma gallisepticum and Mycoplasma synoviae in chickens. Avian Pathol. 25(1):77-92.

[26] Garcia M, Ikuta N, Levisohn S, et al. Evaluation and comparison of PCR assays for detection of Mycoplasma gallisepticum. Avian Dis. 42(3):522-529.

[27] Raviv Z, Kleven SH. Application of real-time PCR for quantitative detection of Mycoplasma gallisepticum. Avian Dis. 48(3):599-605.

[28] Gardin Y, Kempf I, Bradbury JM. Detection of Mycoplasma gallisepticum in tracheal swabs by PCR. Avian Pathol. 24(4):667-678.

[29] Feberwee A, Mekkes DR, de Wit JJ, et al. Comparison of culture, PCR, and serology for detection of Mycoplasma gallisepticum in chickens. Avian Pathol. 34(6):495-500.

[30] Hess M, Neubauer C, Hackl R. Multiplex real-time PCR for simultaneous detection of Mycoplasma gallisepticum and Mycoplasma synoviae. Vet Microbiol. 118(1-2):97-105.

[31] Bencina D. Antimicrobial therapy of Mycoplasma gallisepticum infection. J Antimicrob Chemother. 28(5):673-680.

[32] Kempf I, Reece RL. Antimicrobial susceptibility of avian Mycoplasma species. Vet Microbiol. 41(4):331-340.

[33] Gautier-Bouchardon AV, Ferré S, Le Grand D, et al. Antimicrobial resistance profiles of Mycoplasma gallisepticum isolates from France. Vet Microbiol. 86(1-2):147-154.

[34] Bradbury JM. Antimicrobial resistance in avian mycoplasmas. Br Poult Sci. 45(1):1-10.

[35] Levisohn S, Kleven SH. Avian mycoplasmosis (Mycoplasma gallisepticum). Rev Sci Tech. 19(2):425-442.

[36] Whithear KG, Soeripto, Harrell KZ, et al. Safety and efficacy of the ts-11 strain of Mycoplasma gallisepticum as a live vaccine. Avian Dis. 34(4):888-894.

[37] Evans JD, Leigh SA, Branton SL, et al. Efficacy of the ts-11 and 6/85 vaccines against challenge with a recent field isolate of Mycoplasma gallisepticum. Avian Dis. 51(3):719-724.

[38] Glisson JR, Cheng IH. Inactivated Mycoplasma gallisepticum bacterin in broiler breeders. Avian Dis. 35(3):515-520.

[39] Zhang GZ, Zhang YQ, Hou XL, et al. Recombinant fowlpox virus expressing the GapA protein of Mycoplasma gallisepticum protects chickens. Vaccine. 24(38-39):6430-6436.

[40] Ferguson-Noel NM, Cookson KC, Bennett JE, et al. Efficacy of a recombinant adenovirus-vectored Mycoplasma gallisepticum vaccine in chickens. Avian Pathol. 41(2):175-182.

[41] Kleven SH. Control of avian mycoplasmosis by vaccination. Rev Sci Tech. 16(3):634-641.

[42] Mohammed HO, Carpenter TE, Yamamoto R. Biosecurity for preventing Mycoplasma gallisepticum introduction into poultry flocks. Prev Vet Med. 4(1):35-48.

[43] Halvorson DA, Kelleher CJ, Senne DA. Epidemiology and control of Mycoplasma gallisepticum in turkey flocks. Avian Dis. 32(1):77-86.

[44] National Poultry Improvement Plan. Provisions for Mycoplasma gallisepticum and Mycoplasma synoviae. USDA APHIS.

[45] Marois C, Kempf I, Beven V, et al. Eradication of Mycoplasma gallisepticum from commercial layer flocks using vaccination and test-and-removal. Avian Dis. 50(1):83-88.

[46] Feberwee A, Mekkes DR, de Wit JJ, et al. Comparison of culture, PCR, and serology for detection of Mycoplasma gallisepticum in chickens. Avian Pathol. 34(6):495-500.

[47] Kempf I, Gesbert F, Guittet M, et al. Evaluation of two commercial ELISA kits for the detection of antibodies to Mycoplasma gallisepticum and Mycoplasma synoviae in chickens. Avian Pathol. 25(1):77-92.

[48] Raviv Z, Callison SA, Ferguson-Noel NM, et al. The Mycoplasma gallisepticum GapA cytadhesin is a virulence factor. Infect Immun. 75(12):5634-5643.

[49] Gaunson JE, Philip CJ, Whithear KG, et al. The cellular immune response in chickens infected with Mycoplasma gallisepticum. Avian Pathol. 35(4):291-301.

[50] Bencina D, Bradbury JM, Kleven SH. Transmission of Mycoplasma gallisepticum through the egg. Vet Rec. 124(2):39-40.